Related coverage linked through entity extraction aliases.
May 14, 2026
U.S. insulin glargine and biosimilar developments in 2026 included CivicaScript's low-cost launch and California's CalRx rollout. The global insulin biosimilars market reached US$2.5 billion in 2025 and is projected to reach US$6.0 billion by 2033.
Mar 26, 2026
Amneal Pharmaceuticals recalls magnesium sulfate after a pouch intended for pregnant women was found containing tranexamic acid instead. The medication mix-up could cause serious adverse events including seizures and blood clotting if administered incorrectly.
Dec 22, 2025
The FDA approved multiple denosumab biosimilars in late 2025 and issued REMS safety updates emphasizing severe hypocalcemia risk in patients with advanced chronic kidney disease, including reported hospitalizations and fatalities.
